PURPOSE: The aim of this study was to evaluate the clinical relevance of the simultaneous detection of cytokeratin (CK)-19 messenger RNA (mRNA)- and HER2 mRNA-positive cells in peripheral blood of women with early-stage breast cancer. PATIENTS AND METHODS: CK-19 mRNA- and HER2 mRNA-positive cells were detected using a real-time and a nested reverse-transcriptase polymerase chain reaction assay, respectively, in a cohort of 185 women with early-stage breast cancer before the initiation of any adjuvant systemic treatment. Detection of CK-19 mRNA- and HER2 mRNA-positive cells in the peripheral blood was correlated with clinical outcome. RESULTS: Overall, 63 of the 185 patients (34%) had detectable CK-19 mRNA-positive cells, and 33 (52.3%) also had detectable HER2 mRNA-positive cells. Patients with CK-19/HER2 mRNA-negative cells showed a trend toward longer disease-free survival (DFS) compared with patients with CK-19 mRNA-positive/HER2 mRNA-negative cells (P = .054) and had longer DFS than patients with CK-19/HER2 mRNA-positive cells (P < .001). Similarly, overall survival (OS) was higher in patients with CK-19/HER2 mRNA-negative cells compared with patients with CK-19 mRNA-positive/HER2 mRNA-negative cells (P = .039) or CK-19/HER2 mRNA-positive cells (P < .001). Patients with CK-19/HER2 mRNA-positive cells had shorter DFS but not OS compared with patients with CK-19 mRNA-positive/HER2 mRNA-negative cells. In multivariate analysis, the simultaneous detection of CK-19 mRNA- and HER2 mRNA-positive cells was independently associated with early relapse. CONCLUSION: The simultaneous detection of CK-19 mRNA- and HER2 mRNA-positive cells in peripheral blood predicts poor clinical outcome for women with early-stage breast cancer.
PURPOSE: The aim of this study was to evaluate the clinical relevance of the simultaneous detection of cytokeratin (CK)-19 messenger RNA (mRNA)- and HER2 mRNA-positive cells in peripheral blood of women with early-stage breast cancer. PATIENTS AND METHODS: CK-19 mRNA- and HER2 mRNA-positive cells were detected using a real-time and a nested reverse-transcriptase polymerase chain reaction assay, respectively, in a cohort of 185 women with early-stage breast cancer before the initiation of any adjuvant systemic treatment. Detection of CK-19 mRNA- and HER2 mRNA-positive cells in the peripheral blood was correlated with clinical outcome. RESULTS: Overall, 63 of the 185 patients (34%) had detectable CK-19 mRNA-positive cells, and 33 (52.3%) also had detectable HER2 mRNA-positive cells. Patients with CK-19/HER2 mRNA-negative cells showed a trend toward longer disease-free survival (DFS) compared with patients with CK-19 mRNA-positive/HER2 mRNA-negative cells (P = .054) and had longer DFS than patients with CK-19/HER2 mRNA-positive cells (P < .001). Similarly, overall survival (OS) was higher in patients with CK-19/HER2 mRNA-negative cells compared with patients with CK-19 mRNA-positive/HER2 mRNA-negative cells (P = .039) or CK-19/HER2 mRNA-positive cells (P < .001). Patients with CK-19/HER2 mRNA-positive cells had shorter DFS but not OS compared with patients with CK-19 mRNA-positive/HER2 mRNA-negative cells. In multivariate analysis, the simultaneous detection of CK-19 mRNA- and HER2 mRNA-positive cells was independently associated with early relapse. CONCLUSION: The simultaneous detection of CK-19 mRNA- and HER2 mRNA-positive cells in peripheral blood predicts poor clinical outcome for women with early-stage breast cancer.
Authors: Renata K Kuniyoshi; Flávia de Sousa Gehrke; Beatriz C A Alves; Viviane Vilas-Bôas; Anna E Coló; Naiara Sousa; João Nunes; Fernando L A Fonseca; Auro Del Giglio Journal: Tumour Biol Date: 2015-05-16
Authors: M Banys-Paluchowski; H Schneck; C Blassl; S Schultz; F Meier-Stiegen; D Niederacher; N Krawczyk; E Ruckhaeberle; T Fehm; H Neubauer Journal: Geburtshilfe Frauenheilkd Date: 2015-03 Impact factor: 2.915
Authors: Kostandinos Sideras; David W Hillman; Karthik Giridhar; Brenda F Ginos; Richard C Tenglin; Heshan Liu; Beiyun Chen; Winston Tan; Gerald G Gross; Rex B Mowat; Amylou C Dueck; Edith A Perez; Alvaro Moreno-Aspitia Journal: Oncologist Date: 2022-04-21 Impact factor: 5.837
Authors: Sabine Kasimir-Bauer; Ann-Kathrin Bittner; Lisa König; Katharina Reiter; Thomas Keller; Rainer Kimmig; Oliver Hoffmann Journal: Breast Cancer Res Date: 2016-02-12 Impact factor: 6.466
Authors: Brigitte Rack; Christian Schindlbeck; Julia Jückstock; Ulrich Andergassen; Philip Hepp; Thomas Zwingers; Thomas W P Friedl; Ralf Lorenz; Hans Tesch; Peter A Fasching; Tanja Fehm; Andreas Schneeweiss; Werner Lichtenegger; Matthias W Beckmann; Klaus Friese; Klaus Pantel; Wolfgang Janni Journal: J Natl Cancer Inst Date: 2014-05-15 Impact factor: 13.506